Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019002387) METHOD FOR DETERMINING IF A PATIENT IS AT RISK OF HAVING OR DEVELOPING A COLORECTAL CANCER (CRC)
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/002387 International Application No.: PCT/EP2018/067290
Publication Date: 03.01.2019 International Filing Date: 27.06.2018
IPC:
G01N 33/574 (2006.01)
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
574
for cancer
Applicants:
CENTRE LÉON-BÉRARD [FR/FR]; 28, rue Laennec 69008 LYON, FR
Inventors:
MARIE, Julien; FR
BAUCHE, David; FR
Agent:
COLOMBET, Alain; FR
GROSBOIS, Mathilde; FR
VEINANTE, Aude; FR
MYON, Gérard; FR
GRAND, Guillaume; FR
Priority Data:
17305810.828.06.2017EP
Title (EN) METHOD FOR DETERMINING IF A PATIENT IS AT RISK OF HAVING OR DEVELOPING A COLORECTAL CANCER (CRC)
(FR) PROCÉDÉ PERMETTANT DE DÉTERMINER SI UN PATIENT RISQUE DE PRÉSENTER OU DE DÉVELOPPER UN CANCER COLORECTAL
Abstract:
(EN) The present invention relates to a method for determining if a patient is at risk of having or developing a colorectal cancer (CRC). It further relates to a method for selecting a patient who will most likely benefit from a preventive treatment with an antibiotic, in particular Vancomycin and/or with injections of recombinant human IL-22 and/or anti- human IL-17A antibody.
(FR) La présente invention concerne un procédé permettant de déterminer si un patient risque de présenter ou de développer un cancer colorectal. L'invention concerne en outre un procédé de sélection du patient qui sera le plus susceptible de bénéficier d'un traitement préventif impliquant un antibiotique, en particulier la vancomycine, et/ou des injections d'IL-22 humaine recombinée et/ou d'anticorps anti-IL-17 humaine recombinés.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)